Each segment will focus on a different Mount Sinai research initiative for the treatment of various life-threatening conditions and diseases. The series will begin airing on Science Channel and its social media platforms later this month.
The segments will cover:
- A “digital spinal cord” comprising a microscopic device implanted on the brain to transmit signals and control an exoskeleton or artificial limbs.
- Efforts to implement a new imaging agent and method for the diagnosis of chronic traumatic encephalopathy in living patients with a history of concussions.
- High-tech pop-up Lab100, where data scientists and engineers are combining artificial intelligence, robotics, genomic sequencing, wearable devices and more to individualize the patient experience during medical appointments.
- The development of new technology-based solutions for individuals with brain and spinal cord injuries who need improved access to healthcare.
- Studies of molecular and neurochemical reactions in the brain to understand whether cannabinoids can provide long-lasting therapeutic effects for individuals with opioid addiction.
- The first “digital therapeutic” depression treatment, an app that asks users to identify pictures of faces displaying certain emotions and has been proven in a clinical study to significantly reduce users’ major depressive disorder symptoms.
More articles about health IT:
Brigham and Women’s, Emory and more join radiology AI pilot program
23andMe, Ancestry, Helix form lobbying coalition
Period-tracking app Clue opens database to fertility researchers
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
